Immunocore Holdings PLC (fra:6YG) Share Price

Company Profile

Business description
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Contact
92 Park Drive
Milton Park
AbingdonOxfordshireOX14 4RY
GBR
T: +44 1235438600
E: [email protected]
https://www.immunocore.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
493

Recommended

Shares have dropped 20% in the previous year due to concerns about tariffs.

Esther Holloway | 27 October 2025

Higher gold prices are making a difference to the bottom line but investors overly optimistic.

Jon Mills, CFA | 27 October 2025

We see faster cloud growth and improved longer-term profitability for Alphabet.

Malik Ahmed Khan, CFA | 25 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,298.00	24.00	-0.26%
CAC 40	8,239.18	13.55	0.16%
DAX 40	24,308.78	68.89	0.28%
Dow JONES (US)	47,544.59	337.47	0.71%
FTSE 100	9,653.82	8.20	0.09%
HKSE	26,366.37	67.33	-0.25%
NASDAQ	23,637.46	432.59	1.86%
Nikkei 225	50,419.96	92.36	-0.18%
NZX 50 Index	13,393.98	2.39	0.02%
S&P 500	6,875.16	83.47	1.23%
S&P/ASX 200	9,016.30	12.50	-0.14%
SSE Composite Index	3,994.80	2.15	-0.05%